SFI
ACOR

Susquehanna Fundamental Investments’s Acorda Therapeutics ACOR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$36K Hold
1,130
– – ﹤0.01% 1502
2021
Q4 		$54K Sell
1,130
-60
-5% -$4.13K ﹤0.01% 1364
2021
Q3 		$109K Buy
+1,190
New +$98.7K ﹤0.01% 1614

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna Fundamental Investments's ACOR Position: Q1 2022 in Review

Susquehanna Fundamental Investments held its Acorda Therapeutics (ACOR) position steady in Q1 2022 at 1,130 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Susquehanna Fundamental Investments first reported a position in ACOR in Q3 2021 and has held it in 3 quarters since. The position peaked at $109K in Q3 2021. 31 funds tracked by Wall St. Rank hold ACOR as of Q1 2022.

  • Susquehanna Fundamental Investments held 1,130 shares of Acorda Therapeutics worth $36K as of Q1 2022.
  • Susquehanna Fundamental Investments left its Acorda Therapeutics share count unchanged in Q1 2022.
  • Acorda Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1502 holding.
  • Susquehanna Fundamental Investments first reported a position in Acorda Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Susquehanna Fundamental Investments's Acorda Therapeutics position peaked at $109K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.